At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 12, 2026 at 16:10 ET
The key event is the initiation of a Phase 1 trial for lead candidate EQ504, with proof-of-mechanism data expected in Q2 2027, and a $20M milestone financing closed in October 2026, extending cash runway into 2029.
- First participant dosed in Phase 1 clinical trial of EQ504 in October 2026; proof-of-mechanism data expected Q2 2027
- Closed second tranche of August 2025 private placement for $20M gross proceeds on October 26, 2026
- Cash and cash equivalents $53.3M as of September 30, 2026; pro forma $72.0M including October financing
- Cash runway expected into 2029
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access